Evidence map›Paper›PMID 37779156›Full record

ReviewSignal transduction and targeted therapy2023

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease.

Vivek Panwar, Aishwarya Singh, Manini Bhatt, Rajiv K Tonk, Shavkatjon Azizov, Agha Saquib Raza, Shinjinee Sengupta, Deepak Kumar, Manoj Garg

Open access · goldAbstract readReview
In one paragraph

Review in Signal transduction and targeted therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 575 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
575citing papers in PubMed, 3 pooled it
117.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

575 citing papers in PubMed, 3 syntheses or guidelines pooled it, 760 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

515 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Vivek Panwar *Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Solan, Himachal Pradesh, 173229, India.
Aishwarya Singh *Amity Institute of Molecular Medicine and Stem Cell Research (AIMMSCR), Amity University Uttar Pradesh, Sector-125, Noida, Uttar Pradesh, 201313, India.
Manini BhattDepartment of Biomedical Engineering, Indian Institute of Technology, Ropar, Punjab, 140001, India.
Rajiv K TonkDepartment of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, 110017, India.
Shavkatjon AzizovLaboratory of Biological Active Macromolecular Systems, Institute of Bioorganic Chemistry, Academy of Sciences Uzbekistan, Tashkent, 100125, Uzbekistan.
Agha Saquib RazaRajive Gandhi Super Speciality Hospital, Tahirpur, New Delhi, 110093, India.
Shinjinee SenguptaAmity Institute of Molecular Medicine and Stem Cell Research (AIMMSCR), Amity University Uttar Pradesh, Sector-125, Noida, Uttar Pradesh, 201313, India. shin143@gmail.com.
Deepak KumarDepartment of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Solan, Himachal Pradesh, 173229, India. guptadeepak002@gmail.com.
Manoj GargAmity Institute of Molecular Medicine and Stem Cell Research (AIMMSCR), Amity University Uttar Pradesh, Sector-125, Noida, Uttar Pradesh, 201313, India. nuscsimg@gmail.com.ORCID http://orcid.org/0000-0002-3492-2957
Amity University · INShoolini University · INAcademy of Sciences Republic of Uzbekistan · UZBLK Super Speciality Hospital · INDelhi Pharmaceutical Science and Research University · INIndian Institute of Technology Ropar · IN

Funding

DBT-Wellcome Trust India Alliance IA/E/17/1/503663
6 · The paper itself

Abstract

The mammalian target of rapamycin (mTOR) is a protein kinase that controls cellular metabolism, catabolism, immune responses, autophagy, survival, proliferation, and migration, to maintain cellular homeostasis. The mTOR signaling cascade consists of two distinct multi-subunit complexes named mTOR complex 1/2 (mTORC1/2). mTOR catalyzes the phosphorylation of several critical proteins like AKT, protein kinase C, insulin growth factor receptor (IGF-1R), 4E binding protein 1 (4E-BP1), ribosomal protein S6 kinase (S6K), transcription factor EB (TFEB), sterol-responsive element-binding proteins (SREBPs), Lipin-1, and Unc-51-like autophagy-activating kinases. mTOR signaling plays a central role in regulating translation, lipid synthesis, nucleotide synthesis, biogenesis of lysosomes, nutrient sensing, and growth factor signaling. The emerging pieces of evidence have revealed that the constitutive activation of the mTOR pathway due to mutations/amplification/deletion in either mTOR and its complexes (mTORC1 and mTORC2) or upstream targets is responsible for aging, neurological diseases, and human malignancies. Here, we provide the detailed structure of mTOR, its complexes, and the comprehensive role of upstream regulators, as well as downstream effectors of mTOR signaling cascades in the metabolism, biogenesis of biomolecules, immune responses, and autophagy. Additionally, we summarize the potential of long noncoding RNAs (lncRNAs) as an important modulator of mTOR signaling. Importantly, we have highlighted the potential of mTOR signaling in aging, neurological disorders, human cancers, cancer stem cells, and drug resistance. Here, we discuss the developments for the therapeutic targeting of mTOR signaling with improved anticancer efficacy for the benefit of cancer patients in clinics.

Indexed as

NeoplasmsSirolimusHumansMechanistic Target of Rapamycin Complex 1Proto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesMechanistic Target of Rapamycin Complex 1Proto-Oncogene Proteins c-aktSirolimusTOR Serine-Threonine Kinases

Identifiers

PMID37779156
PMCPMC10543444
OpenAlexW4387230320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.